Systematic review finds rare eosinophilic complications during early dupilumab therapy for type 2 diseases, challenging the need for routine prolonged blood eosinophil monitoring.
Reported eosinophilic complications during dupilumab therapy are extremely rare and mostly develop during the first months of treatment, challenging the need for (prolonged) BEC monitoring during dupilumab therapy. No patient patterns or predictors were identified.
No takes yet. Share an insight, caveat, or question.
Lazzeroni et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: